Abstract
Monitoring radiation therapy (RT) response in glioma patients is at times difficult, with post-RT effects and tumor progression often sharing similar appearances on magnetic resonance imaging. Circulating tumor cell (CTC) analysis provides biologically meaningful information that could contribute to the serial monitoring of treatment response with minimal risk to patients. We have previously established the effectiveness of a telomerase-based CTC assay for glioma. We present herein interim results of a prospective trial in patients with high grade glioma utilizing serial CTC assays throughout the RT course and during follow-up.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
